|
Found 18 result(s) FROM 1963 pages containing the term 'belimumab'.
Wednesday Apr 21, 2010
GSK and Human Genome's Lupus Drug Fails to Meet Secondary Endpoint in Phase III Trial
Effects of the lupus drug Benlysta (belimumab) appear to wane over time...
Wednesday Nov 04, 2009
Joan T. Merrill, MD, Answers Your Top Five Questions About Benlysta and Lupus
Benlysta™ (belimumab, formerly LymphoStat-B®) is poised to be the first new lupus drug approved in 50 years...
Thursday Oct 29, 2009
Benlysta May Be the First New Lupus Drug in 50 Years
Benlysta™ (belimumab, formerly LymphoStat-B®) is poised to be the first new lupus drug in 50 years...
Tuesday Jul 21, 2009
Belimumab Meets Lupus Phase 3 Endpoint
Benlysta® (belimumab, formerly LymphoStat-B) was significantly better that standard care in the phase 3 BLISS-52 trial...
Monday Jun 16, 2008
Belimumab is Back: New Criteria Show Activity in SLE
The humanized monoclonal antibody belimumab showed significant activity in the extension of a phase II clinical trial for SLE as measured by new, FDA-approved assessment criteria...
Friday Oct 05, 2007
Future Looks Bright for Sjögren's Syndrome Patients
B- and T-cell targeted therapies as well as other biologic drugs may change the way primary Sjögren's syndrome is treated in the future...
Wednesday Sep 26, 2007
Wanted: Lupus Patients for Clinical Trials
The lupus therapeutic landscape is changing slowly but dramatically, and more patients are needed to help speed the development of new drugs…
Friday Jun 22, 2007
Belimumab Improves Symptoms in Nearly Half of Lupus Patients at 52 Weeks, Advances to Phase III Studies
Belimumab produces sustained improvement in SLE symptoms…
Friday Jun 01, 2007
HGS and GSK Initiate Second Phase III Clinical Trial of LymphoStat-BR (Belimumab) in Lupus
Human Genome Sciences, Inc. announced that dosing has begun in BLISS-52, the second of two pivotal phase III clinical trials of LymphoStat-B® (belimumab), a human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS®), in patients with active systemic lupus erythematosus (SLE).
Wednesday May 23, 2007
New SLE Treatments Hit B-Cells From Several Directions
Various new treatments directed at B-cells offer mounting interest in SLE arsenal...
Thursday Feb 15, 2007
HGS and GSK Initiate Phase III Clinical Trial of LymphoStat-B® in Lupus
Human Genome Sciences, Inc and GlaxoSmithKline PLC announced the initiation of dosing in BLISS-76, one of two pivotal phase III clinical trials of LymphoStat-B® (belimumab, a human monoclonal antibody that blocks the biological activity of B-lymphocyte stimulator, or BLyS®) in patients with active systemic lupus erythematosus (SLE)...
Thursday Aug 10, 2006
HGS to Initiate Phase III Trials of LymphoStat-B in Lupus; to Receive $24 Million from GSK
Human Genome Sciences, Inc. announced its phase III clinical development plans for LymphoStat-Bâ„¢ (belimumab, a human monoclonal antibody that specifically inhibits the biological activity of B-lymphocyte stimulator [BLyS], a protein required for the development of B-lymphocyte cells into mature plasma B cells) in patients with active systemic lupus erythematosus (SLE).
Thursday Jul 27, 2006
ZymoGenetics Report Positive Preliminary Findings from Atacicept (TACI-Ig) Phase Ib Studies in Patients with Lupus
ZymoGenetics, Inc, announced preliminary positive findings from two phase Ib clinical trials in patients with systemic lupus erythematosus (SLE) treated with atacicept.
Wednesday Jan 18, 2006
Human Genome Sciences to Advance LymphoStat-Bâ„¢ to Phase III in Lupus
Human Genome Sciences, Inc, announced plans to initiate in 2006 a phase III clinical trial of LymphoStat-Bâ„¢ (belimumab)...
Tuesday Nov 22, 2005
Belimumab Data Show Only Modest Clinical Effect in RA
While belimumab is biologically active, safe, and somewhat effective for RA, the magnitude of its effect may not portend a bright future for the novel anti-BlyS agent... Presented at: 69th Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif. Abstract 1920.
Thursday Oct 06, 2005
Human Genome Sciences' LymphoStat-Bâ„¢ for Lupus Fails to Meet Primary Endpoints in Phase II Trial
Human Genome Sciences, Inc (Rockville, Md), announced that its investigational drug for lupus, LymphoStat-Bâ„¢, (belimumab) failed to meet the overall primary efficacy endpoints...
Monday Jul 18, 2005
GSK and HGS to Jointly Develop LymphoStat-BTM for RA and Lupus
Human Genome Sciences, Inc. (HGS) announced that GlaxoSmithKline (GSK) has exercised its option under a 1996 agreement to co-develop and commercialize LymphoStat-B (belimumab), a human monoclonal antibody (created through a collaboration with Cambridge Antibody Technology) that neutralizes the activity of B-lymphocyte stimulator, or BlySTM, a protein required for the development of B-lymphocytes into mature plasma B cells.
Wednesday Apr 13, 2005
Human Genome Sciences' LymphoStat-B® Meets Primary Efficacy and Safety Endpoints in Phase II trial for RA
Human Genome Sciences, Inc. reported results from a double-blind, placebo-controlled, multi-center Phase II clinical trial indicating that LymphoStat-B (belimumab) administered intravenously is safe, well tolerated, and results in a statistically significant reduction in the signs and symptoms of rheumatoid arthritis (RA).
|
